ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

34128 results sorted by trial registration date.
  • The effect of virtual reality induced optic flow manipulations during cycling on exercise engagement, experiences, and clinical outcomes in people with knee osteoarthritis

    Despite clinical guidelines recommending exercise for the management of knee osteoarthritis (OA), many Australians with painful knee OA are physically inactive. Pain during exercise can reduce initial and sustained exercise engagement, making it difficult for people with knee OA to maintain regular exercise. Although exercise can improve pain, function, and long-term health outcomes, new strategies are needed to improve exercise uptake and engagement in people with arthritis. Virtual reality (VR) technology holds promise as a strategy to reduce exercise barriers and increase exercise engagement and experiences, and thus, have greater effects on clinical outcomes including knee pain and physical function. This study will use a parallel-group randomised trial design. Participants will be randomised to one of two active treatment groups: VR-enhanced cycling with increased optic flow or VR-enhanced cycling with decreased optic flow. Both groups will receive two in-person, one-on-one treatment sessions per week over six weeks (total of twelve sessions). The sessions will be delivered by an allied health professional (physiotherapist, occupational therapist). The primary outcomes will be exercise engagement (total work during cycling) and experiences (affective valance via Feeling Scale). Secondary outcomes will include knee pain (WOMAC pain subscale), physical function (WOMAC function subscale), knee pain intensity during cycling (101-point NRS), perceived exertion during cycling (Borg scale), exercise engagement (average/maximal power, cycling duration), exercise enjoyment (101-point NRS, Physical Activity Enjoyment Scale), physical activity (The Active Australia survey), pain interference (BPI-PI), and motion sickness symptoms during cycling (FMS), pain self-efficacy (PSEQ), health related quality of life (EQ-5D), pain-related fear of movement (Brief FoM), bodily perception of the knee (FreKAQ), knee osteoarthritis conceptualization (OACS), pain catastrophizing (PCS), positive and negative affect (PANAS-SF), psychological distress (PHQ-4), fatigue level (ROF) and treatment expectation.

  • A Phase 1/2, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 valent Human Papillomavirus Virus (10vHPV) Vaccine in Comparison with Gardasil 9 Vaccine in Healthy Adults

    Human papilloma virus (HPV) is the most common viral infection of the reproductive system and is spread through contact with infected genital skin, mucous membranes, or bodily fluids. This study will assess an experimental vaccine called 10vHPV for the safety, reactivity, and immune response, in healthy adults, compared to Gardasil 9. There are two phases in this study - Phase 1 will include up to 36 healthy adults aged 18-25 years, Phase 2 will include 36 healthy adults aged 26-45 years. Participants will be randomised in a 2-to-1 ratio to receive either 10vHPV or Gardasil 9. 10vHPV or Gardasil 9 will be administered as a 0.5 mL single dose via intramuscular injection in the deltoid muscle of the upper arm. In Phase 1, participants will receive a single dose on Day 1, and in Phase 2, participants will receive a single dose on Day 1, then at 2 months (Day 60), and again at 6 months (Day 180). In Phase 1, the main objective is to assess the safety of a single dose of 10vHPV vaccine, compared to Gardasil 9, in healthy adults aged 18 to 25 years. In Phase 2, the main objective is to assess the safety of 3 doses of 10vHPV vaccine, compared to 3 doses of Gardasil 9 vaccine, in healthy adults aged 26 to 45 years.

  • Body composition and cardiometabolic health across the menopause transition in Australian women

    This research project aims to investigate the complex relationship between hormonal changes during the menopausal transition and subsequent alterations in body composition, fat distribution, and metabolic parameters. Despite the well-documented increase in cardiovascular and metabolic disease risk following menopause, there remains a significant knowledge gap regarding the precise temporal relationship between hormonal shifts and body composition changes. This prospective longitudinal study will track women through the menopausal transition, employing advanced body composition assessment techniques and comprehensive metabolic profiling to establish clearer causative relationships and identify potential intervention windows.

  • In people with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), does exercise training improve liver fibro-inflammation?

    Exercise is considered a cornerstone of therapy for type 2 diabetes (T2D) and for related metabolic dysfunction-associated fatty steatotic disease (MASLD). However, the benefits of exercise on liver fibroinflammation are unclear. Fibro-inflammation develops as MASLD progresses and is more likely to occur in people with T2D. Liver fibrosis is a key prognostic indicator for liver-related mortality. Moreover, long-term exercise maintenance remains a challenge to sustained health benefits in T2D and MASLD. This study will examine the efficacy of a 12-wk aerobic exercise intervention followed by 12-weeks self-directed maintenance supported by adherence building strategies for reducing liver fibro-inflammation, compared with a supervised stretch comparator. It is hypothesised that 12-wks of aerobic and resistance exercise will improve fibro-inflammation significantly more than the stretch control, and that improvement will be sustained at 12 weeks post intervention if exercise is also sustained. We hypothesise that benefits will be maintained at 12 months follow-up so long as exercise has been maintained.

  • D-Cycloserine Augmentation of Optimised Accelerated TMS for Treatment Resistant Depression (END-Depression study)

    Major depressive disorder (MDD) is a common mental health condition, and many people do not improve with standard treatments such as antidepressant medications. This study is investigating whether a more personalised form of transcranial magnetic stimulation (TMS), a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain, can improve outcomes for people with treatment-resistant depression. Instead of using standard methods to identify where to stimulate the brain, this approach uses MRI scans to target brain areas that are more closely linked to depression. The study will also use an accelerated treatment schedule, with multiple TMS sessions each day over five consecutive days, which may be more effective than the standard once-daily approach. In addition, the study will investigate whether taking a 100 mg dose of D-cycloserine (DCS), a medication that may enhance the brain's response to TMS, before the first treatment session each day further improves outcomes compared with placebo.

  • Mental Health Begins at Birth: Exploring the Impact of Psychological Treatment on Parent-Infant Relationships and Child Mental Health in Mothers Experiencing Childbirth-Related Posttraumatic Stress Disorder

  • WHISPER-ICU: A study evaluating the effect of white noise on total sleep time in non-ventilated patients in the Intensive Care Unit

    This study aims to determine whether playing white noise overnight can improve sleep for patients in the intensive care unit who are not receiving mechanical ventilation. Poor sleep is common in the ICU because of noise from alarms, equipment, staff activity and patient care. Patients in the study will experience both a night with white noise and a night without white noise, allowing their sleep to be compared between the two conditions. Sleep will be assessed using a wrist-worn activity monitor (actigraphy) and a patient-completed sleep questionnaire (Richards-Campbell Sleep Questionnaire). The study will also examine how closely sleep measurements from the activity monitor agree with patients’ own assessments of their sleep.

  • Plasmalogen supplementation for cognitive function in adolescents with Postural Orthostatic Tachycardia Syndrome (POTS): a pilot study.

    This pilot randomised controlled trial will evaluate the feasibility, acceptability and safety of Hokkaido Scallop Oil Plasmalogen (HSOP) supplementation in adolescents aged 13–18 years with Postural Orthostatic Tachycardia Syndrome (POTS). Participants will be randomised to receive HSOP or placebo for 90 days. The study will assess recruitment, retention, adherence, data completeness and safety outcomes, while exploring effects on cognitive function, symptoms, quality of life, heart rate responses and plasma plasmalogen concentrations. Findings will inform the design of a future larger-scale randomised controlled trial.

  • Acceptance and Commitment Therapy (ACT) based workshops to build resilience in care economy students in Vocational Education and Training (VET)

    The study aims to find the effectiveness of an Acceptance and Commitment Therapy (ACT) based workshops on the resilience levels of students enrolled in health and community services in Vocational Education and Training (VET). The study includes a series of 4 workshops held weekly based on 6 core skills of ACT; cognitive defusion, acceptance, committed action, values, self as context and contact with the present moment. The CD-RISC 25 scale will be used to measure the resilience levels of students pre and post intervention.

  • Evaluating a Trauma-Informed Cognitive Rehabilitation Intervention for Cancer Survivors

    This study will assess the effect of a trauma-informed cognitive rehabilitation program - Tri-eReCog - on the cognitive and distress symptoms in a group of cancer survivors. Who is it for? You may be eligible for this study if you are an adult aged 18 years or older, you have been diagnosed with non-central nervous system cancer, completed your primary treatment for cancer at least 6 months prior to enrolment (excluding ongoing hormone therapy), you feel that you have distress symptoms (either post-traumatic stress, depression and/or anxiety symptoms) and cognitive impairment (e.g., forgetfulness, inability to concentrate, trouble with multi-tasking), and you have no anticipated cancer treatments - apart from hormonal medications. Study details Participants who choose to enrol in this study will be randomly alloacated by chance (similar to flipping a coin) to either receive access to the Tri-eReCog online program, or join a waitlist to access the program after 6 weeks. Participants allocated to the Tri-eReCog program will be asked to complete 5 modules over 5 weeks (one module per week). It is expected that each module will take between 30-60 minutes to complete. Participants allocated to the waitlist group will not receive access to the program during the main study, but all participants will be asked to complete questionnaires before and after they interact with the Tri-eReCog program (or after 6 weeks have passed if in the waitlist group). It is hoped this research will demonstrate that use of the Tri-eReCog program leads to reductions in depression, anxiety and/or post-traumatic stress symptoms as well as reductions in self-reported cognitive impairment. If this study shows that Tri-eReCog is beneficial for cancer survivors, the program may be expanded to enable a greater number of cancer survivors to access the modules.

Tags:
  • Finding clinical trials